Patents Assigned to John Wyeth & Brothers Limited
  • Patent number: 6395902
    Abstract: Compounds having the formula R5O—A—NR4—R2  (V) where R2 is a heteroaryl group linked to the remainder of the molecule via a carbon atom adjacent a nitrogen atom and R4 and R5 are both hydrogen atoms or together represent —SO— or —SO2— and A is C2-C4 alkylene optionally substituted by one or more lower alkyl groups are novel intermediates in the preparation of pharmaceutically useful piperazine derivatives as end compounds. The compounds having formula V where R4 and R5 are hydrogen may be prepared by a rearrangement of a compound having the formula (VI).
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: May 28, 2002
    Assignee: John Wyeth & Brother Limited
    Inventors: Christopher Ian Brightwell, Robin Gerald Shepherd
  • Patent number: 5821251
    Abstract: This invention concerns a compounds of generic formula: ##STR1## or a pharmaceutically acceptable salt thereof, where the dotted lines represent optional bonds with the nitrogen ring optional bonds being between one adjacent pair on ring atoms,R.sup.3 is an optionally substituted C.sub.6 -C.sub.10 aryl or heteroaryl group; said aryl or heteroaryl radicals being optionally substituted by one or more substituents the same or different,R.sup.4 represents hydrogen, or a group of formula --CR.sup.a R.sup.b R.sup.c where R.sup.a, R.sup.b and R.sup.c are independently selected from hydrogen, C.sub.1 -C.sub.6 alkyl, optionally substituted C.sub.6 -C.sub.10 aryl, optionally substituted heteroaryl, C.sub.1 -C.sub.6 alkyl substituted by optionally substituted C.sub.6 -C.sub.10 aryl or heteroaryl,R' represents one or more optional substituents the same or different, selected from one or more of the following: halogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.7 alkoxycarbonyl, C.sub.1 -C.sub.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: October 13, 1998
    Assignee: John Wyeth & Brother Limited
    Inventors: Roger Crossley, Albert Opalko, Peter Jonathan Meade, Barry John Langham
  • Patent number: 5763460
    Abstract: Compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof are 5-HT.sub.1A binding agents and may be used, for example, as anxiolytics. In the formula a and b each represents 0, 1, 2 or 3 such that the sum of a+b is 0, 1, 2 or 3, the dotted line represents an optional double bond which may be present in the ring, provided that a is at least 1, A is an alkylene chain of 1 or 2 carbon atoms optionally substituted by one or more lower alkyl groups, R is a mono or bicyclic aryl or heteroaryl radical with the proviso that R is not an unsubstituted phenyl group, R.sup.1 is a mono or bicyclic heteroaryl radical, and R.sup.2 is cycloalkyl or cycloalkenyl.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: June 9, 1998
    Assignees: John Wyeth & Brother Limited, American Home Products Corporation
    Inventors: Ian Anthony Cliffe, Terence James Ward, Chapman White Alan, Antony Ashwell Mark, Bernhard Baudy Reinhardt
  • Patent number: 5637701
    Abstract: A novel asymmetric synthesis is provided for preparing optically active amides of formula (A) and their salts. ##STR1## In the formula, X represent --N-- or --CH--, R represents a mono or bicyclic aryl or heteroaryl group, R.sup.1 is an aryl or heteroaryl radical, and R.sup.2 and R.sup.3 have specified meanings. The products are useful as 5-HT.sub.1A antagonists.Novel diesters of formula D useful as intermediates in the process are also disclosed.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: June 10, 1997
    Assignee: John Wyeth & Brother, Limited
    Inventor: Mark A. Ashwell
  • Patent number: 5604238
    Abstract: This invention concerns compounds having the Z-configuration of formula: ##STR1## or salts thereof, wherein R represents an optionally substituted aryl or heteroaryl radical, R.sup.1, R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, (C.sub.1 -C.sub.6 alkoxy)carbonyl, carboxy, hydroxy (C.sub.1 -C.sub.6)alkyl, halogen, halo(C.sub.1 -C.sub.6)alkyl, carboxy(C.sub.1 -C.sub.6)alkyl, optionally substituted aryl or heteroaryl or optionally substituted aralkyl or heteroarylalkyl; n represents 0, 1 or 2; R.sup.4 and R.sup.5 each independently represent hydrogen or a substituent selected from lower alkyl, optionally substituted aryl and optionally substituted aralkyl or R.sup.4 and R.sup.5 are geminal C.sub.1 -C.sub.6 alkyl substituents and R.sup.6 is hydrogen or C.sub.1 -C.sub.6 alkyl which possess antiinflammatory activity.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 18, 1997
    Assignee: John Wyeth & Brothers Limited
    Inventors: Roger Crossley, Albert Opalko
  • Patent number: 5585374
    Abstract: Amide derivatives of formula (I) and their pharmaceutically acceptable salts (where a and b each represent 0, 1, 2 or 3 such that a+b=0, 1, 2 or 3, the dotted line represents an optional double bond, A is an optionally substituted C.sub.1-2 -alkylene chain, R is mono or bicyclic aryl or heteroaryl radical, R.sup.1 is hydrogen or lower alkyl, R.sup.2 is an aryl, aralkyl, heteroaryl or heteroarylalkyl and --CONR.sup.3 R.sup.4 represents a specified amide group) are 5-HT.sub.1A binding agents and may be used, for example, as anxiolytics.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: December 17, 1996
    Assignee: John Wyeth Brother, Limited
    Inventors: Ian A. Cliffe, Alan C. White
  • Patent number: 5541326
    Abstract: Piperazine derivatives of formula: ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula, n is 1 or 2; R and R.sup.5 are hydrogen or lower alkyl, R.sup.1 is substituted or unsubstituted aryl or a heteroaromatic radical; R.sup.3 is substituted or unsubstituted aryl or substituted or unsubstituted arylalkyl; R.sup.9 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl or substituted or unsubstituted arylalkyl with the proviso that when R.sup.9 is hydrogen, alkyl, or arylalkyl, R.sup.5 is other than a tertiary alkyl group. The compounds of this invention are useful 5-HT.sub.1A antagonists for the treatment of CNS disorders such as anxiety.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: July 30, 1996
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: 5538956
    Abstract: This invention concerns compounds of formula (I) wherein E represents hydrogen, C.sub.1 -C.sub.6 alkyl or a group Ar.sup.1 -A.sup.1 ; Ar and Ar.sup.1 when present each represent an aryl group of 6 to 10 carbon atoms or a heteroaryl group of 5 to 10 ring atoms wherein the heteroatoms are selected from oxygen, nitrogen and sulphur, which may be optionally substituted by one or more substituents selected from alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen, haloalkyl of 1 to 6 carbon atoms, haloalkoxy of 1 to 6 carbon atoms, cyano, amino, mono- or di-(C.sub.1 -C.sub.6) alkylamino, hydroxy and nitro; A and A.sup.1 when present are the same or different alkylene groups having one or two carbons linking Ar or Ar.sup.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: July 23, 1996
    Assignee: John Wyeth & Brother, Limited
    Inventors: Michael C. Minchin, John F. White
  • Patent number: 5532242
    Type: Grant
    Filed: July 7, 1994
    Date of Patent: July 2, 1996
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: 5527955
    Abstract: The invention concerns a method for treating depression or senile dementia using a compound which acts selectively as an agonist of gamma aminobutyric acid (GABA) at GABA autoreceptors with the proviso that the compound is not fengabine and progabide.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: June 18, 1996
    Assignee: John Wyeth & Brother, Limited
    Inventors: Michael C. W. Minchin, John F. White
  • Patent number: 5436251
    Abstract: (Endo)-N-[[[8-azabicyclo[3.2.1]octan-3-yl]amino]carbonyl]-2-(cyclopropylmet hyloxy)benzamide and pharmaceutically acceptable salts thereof possess 5-HT.sub.3 antagonistic activity and are useful in the treatment of neuro-psychiatric disorders (e.g. anxiety), gastro-intestinal disorders and migraine.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: July 25, 1995
    Assignee: John Wyeth & Brother, Limited
    Inventors: Terence J. Ward, Gerald Bradley
  • Patent number: 5422355
    Abstract: The invention concerns compounds having formula: ##STR1## or a salt thereof, wherein E represents hydrogen, lower alkyl or a group Ar.sup.1 --A.sup.1 --; Ar and Ar.sup.1 are the same or different aryl groups (including heteroaryl) which are optionally substituted, eg by one or more substituents commonly used in pharmaceutical chemistry; A and A.sup.1 are the same or different alkylene groups having one or two carbon atoms linking Ar or Ar.sup.1 to N and optionally substituted by lower alkyl and/or optionally substituted aryl, B is an alkylene group of 3 or 4 carbon atoms, which may be substituted by lower alkyl; D.sup.1 represents halogen, CH.sub.3, CR.sup.1 R.sup.2 NH.sub.2, SO.sub.3 H or SO.sub.2 NR.sup.6 R.sup.7 where R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl and R.sup.6 and R.sup.7 are each hydrogen, lower alkyl or aralkyl of 7 to 12 carbon atoms or R.sup.6 and R.sup.
    Type: Grant
    Filed: June 24, 1993
    Date of Patent: June 6, 1995
    Assignee: John Wyeth & Brother, Limited
    Inventors: John F. White, Michael C. W. Minchin, Christine Ennis
  • Patent number: 5420278
    Abstract: Piperazine derivatives of formula ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula n is 1 or 2, R is hydrogen or lower alkyl, R.sup.1 is an aryl or nitrogen containing heteroaryl radical, R.sup.2 is hydrogen or lower alkyl, R.sup.3 is aryl, C.sub.4-8 alkyl or aryl(lower)alkyl and X is a functionalized group of specified meaning. The compounds exhibit activity as 5-HT.sub.1A antagonists and can be used, into alia, for the treatment of CNS disorders, such as anxiety.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: May 30, 1995
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: 5382583
    Abstract: Piperazine derivatives of formula: ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula, n is 1 or 2; R and R.sup.5 are hydrogen or lower alkyl, R.sup.1 is substituted or unsubstituted aryl or a heteroaromatic radical; R.sup.3 is substituted or unsubstituted aryl or substituted or unsubstituted arylalkyl; R.sup.9 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl or substituted or unsubstituted arylalkyl with the proviso that when R.sup.9 is hydrogen, alkyl, or arylalkyl, R.sup.5 is other than a tertiary alkyl group. The compounds of this invention are useful 5-HT.sub.1A antagonists for the treatment of CNS disorders such as anxiety.
    Type: Grant
    Filed: December 29, 1992
    Date of Patent: January 17, 1995
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: 5369103
    Type: Grant
    Filed: June 19, 1992
    Date of Patent: November 29, 1994
    Assignee: John Wyeth & Brother, Limited
    Inventors: Ian A. Cliffe, Alan C. White, Anderson D. Ifill
  • Patent number: 5364849
    Abstract: Piperazine derivatives of formula ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula n is 1 or 2, R is hydrogen or lower alkyl, R.sup.1 is an aryl or nitrogen containing heteroaryl radical, R.sup.2 is hydrogen or lower alkyl, R.sup.3 is aryl, C.sub.4-8 alkyl or aryl(lower)alkyl and X is a functionalised group of specified meaning. The compounds exhibit activity as 5-HT.sub.1A antagonists and can be used, into alia, for the treatment of CNS disorders, such as anxiety.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: November 15, 1994
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: 5346896
    Abstract: Disclosed herein are piperazine derivatives of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein W is (CH.sub.2).sub.m, CHOH or O,m is one of the integers 1 or 2,A is an alkylene chain of 1 to 3 carbon atoms optionally substituted by one or more (lower)alkyl groups,R is hydrogen or lower alkyl,R.sup.1 and R.sup.2 are each, independently, aryl or heteroaryl radicals with the proviso that R.sup.1 is not an optionally substituted indolyl radical,R.sup.3 is hydrogen or lower alkyl andR.sup.4 is an aryl or heteroaryl radical.The compounds are 5HT.sub.1A binding agents which may be used, for example, in the treatment of CNS disorders such as anxiety.
    Type: Grant
    Filed: June 3, 1992
    Date of Patent: September 13, 1994
    Assignee: John Wyeth & Brother, Limited
    Inventors: Terence J. Ward, Graham J. Warrellow
  • Patent number: 5340812
    Abstract: Piperazine derivatives of formula ##STR1## and their pharmaceutically acceptable acid addition salts are disclosed. In the formula n is 1 or 2, R is hydrogen or lower alkyl, R.sup.1 is an aryl or nitrogen containing heteroaryl radical, R.sup.2 is hydrogen or lower alkyl, R.sup.3 is aryl, C.sub.4-8 alkyl or aryl(lower)alkyl, and X is a functionalised group of specified meaning. The compounds exhibit activity as 5-HT.sub.1A antagonists and can be used, inter alia, for the treatment of CNS disorders, such as anxiety.
    Type: Grant
    Filed: January 7, 1993
    Date of Patent: August 23, 1994
    Assignee: John Wyeth & Brother, Limited
    Inventor: Ian A. Cliffe
  • Patent number: D370625
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: June 11, 1996
    Assignee: John Wyeth & Brother Limited
    Inventors: Stephen F. Kelsey, Donald Williams
  • Patent number: D404641
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 26, 1999
    Assignee: John Wyeth & Brother Limited
    Inventors: Stephen Frederick Kelsey, Donald Williams